GSK shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for chronic cough after ...

GSK drops camlipixant's refractory chronic cough program after mixed phase III results, but the drug remains in a phase IIb ...

Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning ...

GSK (GSK) stock slips as the company discontinues a cough therapy added from its $2B Bellus Health acquisition following a ...

The Centers for Disease Control and Prevention may have handed Republican leaders a political grenade with the pin pulled. On ...

Shares in GSK fell sharply on Friday after the pharma titan announced it was stopping the development of a refractory chronic ...

GSK plc provides an update on the CALM-1 and CALM-2 phase III clinical trials, which assessed the efficacy and safety of two doses of camlipixant (a P2X3 receptor antagonist) in adults with refractory ...

Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced that it will be presenting a poster ...

After GSK (GSK) announced it would discontinue a chronic cough therapy following a late-stage trial failure, Trevi ...

GSK plc is halting work with camlipixant, a P2X3 receptor antagonist, in adults with refractory chronic cough (RCC) after reporting mixed results from the Calm-1 and Calm-2 phase III trials. The first ...

GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the ...

Climate change, pollution, and longer allergy seasons are increasing persistent coughs, slowing recovery, and raising ...